I would not be tempted by $25 unless it also came with stock in the new company. The science continues to impress and shows no signs of slowing as to the number of indications that leronlimab could be used for.

BMY just failed in their trial for multiple myeloma and sent their stock price down 6% today. CYDY is going to be in a bidding war between the BP's at some point.